Community Considerations in Relapsed/Refractory Multiple Myeloma: Current and Developing Anti-BCMA Therapies
Post-Test/Evaluation

Questions marked with a * are required

32%

Contact Information

First Name

Last Name

Email Address

Credentials/Degree (MD, DO, RN, etc.)

Date of Participation

Are you a Physician?

Yes

No

Which of the following statements are TRUE regarding development of resistance in multiple myeloma?

A. Resistance develops as a result of reduced binding affinity to multiple myeloma cell targets

B. Resistance develops as a result of increased mutational burden in target cells

C. Resistance results from proliferation of subclones of multiple myeloma cells that are less susceptible to therapy

D. Resistance results from proliferation of subclones of multiple myeloma cells that are more susceptible to therapy

E. None of the above

Which of the following therapies does NOT target B-cell maturation antigen?

A. Idecabtagene vicleucel

B. Ciltacabtagene autoleucel

C. Belantamab mafodotin

D. Linvoseltamab

E. Selinexor

CM is a patient aged 65 years with multiple myeloma that has relapsed after 4 prior lines of therapy, including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory drug. Which of the following therapies is/are currently available off-the-shelf and may be initiated in this patient?

A. Belantamab mafodotin

B. Idecabtagene vicleucel

C. Ciltacabtagene autoleucel

D. Teclistamab

E. Any of the above

GR is a patient considering clinical trials of therapy with a bispecific antibody. Which of the following adverse events occurs LEAST frequently at grade 3 or 4 severity levels with bispecific antibodies in clinical trials?

A. Anemia

B. Thrombocytopenia

C. Neutropenia

D. Lymphopenia

E. Cytokine release syndrome

GR is interested in the overall likelihood of response to therapy with bispecific antibodies in development targeting BCMA and CD3. What are approximate overall response rates at therapeutic doses in clinical trials of BCMA-targeted bispecific antibodies to date?

A. 10%-15%

B. 15%-20%

C. 20%-30%

D. 30%-50%

E. 60%-80%

Powered by QuestionPro

Loading...